Provided is a T-cell receptor (TCR), which has the property of binding to a YMLDLQPET-HLA A0201 complex. The binding affinity of the TCR to the YMLDLQPET-HLA A0201 complex is at least two times that of a wild-type TCR to the YMLDLQPET-HLA A0201 complex. Also provided is a fusion molecule of such TCR and a therapeutic agent. Such TCR can be used alone or in combination with a therapeutic agent so as to target tumor cells presenting the YMLDLQPET-HLA A0201 complex.
展开▼